Announcement under Regulation 30 (LODR)-Change in Management
Filed with BSE · · 2 pages · English
Summary by 6ix AI
Goldline Pharmaceutical Ltd. has announced a change in management regarding the appointment of a new internal auditor. The firm specializes in corporate law advisory and compliance management, among other services. This filing serves to inform stakeholders in accordance with regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Goldline Pharmaceutical Ltd. on 6ix
Earlier from Goldline Pharmaceutical
- Board Meeting Outcome for Outcome Of Board Meeting Held Today, I.E., 09Th June, 2026
- Outcome Of Board Meeting Held Today, I.E., 09Th June, 2026
- Goldline Pharmaceutical Ltd. Press Release Jun 02 2026
- Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 To Be Held On Tuesday, June 09, 2026.
- Goldline Pharmaceutical Ltd. Press Release May 27 2026
Later from Goldline Pharmaceutical
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
- Goldline Pharmaceutical Ltd. Press Release Jun 24 2026
- Goldline Pharmaceutical Ltd. Press Release Jul 14 2026
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Goldline Pharmaceutical Ltd. Press Release Jul 20 2026
Follow Goldline Pharmaceutical into a list and get an email when it puts out news.
Follow Goldline Pharmaceutical